Lenvatinib Shows Promising Activity in RET+ NSCLC

Treatment with the kinase inhibitor lenvatinib demonstrated promising activity in patients with RET-positive NSCLC.
Treatment with the kinase inhibitor lenvatinib demonstrated promising activity in patients with RET-positive NSCLC.

Treatment with the kinase inhibitor lenvatinib demonstrated promising activity in patients with RET-positive non-small cell lung cancer (NSCLC), a study presented at the European Society for Medical Oncology (ESMO) 2016 Congress has shown.1

Because RET fusions activate RET kinase and occur in 1% to 2% of patients with adenocarcinoma of the lung, researchers sought to evaluate the activity and tolerability of lenvatinib in this patient population.

For the open-label, phase 2 study (ClinicalTrials.gov Identifier: NCT01877083), investigators enrolled 25 patients with RET-positive NSCLC. Of those, 13 had KIF5B-RET and 12 had other RET fusion proteins. More than half had received at least 2 prior lines of therapy, 28% had prior RET therapy, and 8% had no prior therapy.

Results showed that the overall response rate was 16%, with 14% and 17% of those receiving and not receiving prior RET therapy achieving a response, respectively. Median duration of treatment was 16 weeks.

Median progression-free survival was 7.3 months (95% CI, 3.6-10.2) and median overall survival had not yet been reached (95% CI, 5.8-not evaluable).

Researchers also found that the disease control rate and clinical benefit rate were 76% and 48%, respectively, overall. Among patients who had received prior RET therapy, the disease control rate was 86% vs 72% for patients who had not had prior RET treatment.

The most common treatment-emergent adverse events were hypertension, nausea, decreased appetite, diarrhea, proteinuria, and vomiting. In total, 92% of patients experienced grade 3 or worse treatment-emergent adverse events, with 1 patient dying due to pneumonia potentially related to lenvatinib treatment.

The findings ultimately suggest that further evaluation of lenvatinib in patients with RET-positive NSCLC is warranted.                                     

Reference

1. Velcheti V, Hida T, Reckamp KL, et al. Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung. Poster presented at: European Society for Medical Oncology (ESMO) 2016 Congress; October 7-11, 2016; Copenhagen, Denmark.
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs